Labcorp Expands DPYD Test to Cover All AMP-Recommended Variants for Safer Chemotherapy — Labcorp Holdings Inc.

Event summary

Labcorp has expanded its DPYD Genotyping test to cover all Tier 1 and Tier 2 variants recommended by the Association for Molecular Pathology (AMP).
The test helps identify cancer patients at risk for severe side effects from fluoropyrimidine chemotherapy, such as 5-FU and capecitabine.
Approximately 9% of patients carry DPYD variants that impair their ability to metabolize these drugs, leading to an estimated 1,300 deaths annually in the U.S. from 5-FU toxicity.
The expansion strengthens Labcorp's pharmacogenomics and oncology portfolio, complementing its existing hereditary cancer testing and precision oncology offerings.

The big picture

Labcorp's expansion of its DPYD test underscores the growing emphasis on personalized medicine in oncology, particularly as regulatory bodies like the FDA and NCCN increasingly recommend pharmacogenomic testing to mitigate chemotherapy risks. This move positions Labcorp to capitalize on the broader trend toward precision oncology, where genetic testing plays a critical role in tailoring treatments and improving patient outcomes. The company's long-standing presence in pharmacogenomics, coupled with this expansion, reinforces its ability to support safer, more personalized cancer care across the patient journey.

What we're watching

Adoption Pace: How quickly clinicians will integrate the expanded DPYD test into standard pre-chemotherapy protocols.
Regulatory Alignment: Whether the expanded test will further align with evolving FDA and NCCN guidelines for chemotherapy safety.
Market Differentiation: The extent to which Labcorp can leverage this expansion to solidify its leadership in pharmacogenomics and oncology diagnostics.